Strober B, Mallya UG, Yang M, et al. - In patients with atopic dermatitis (AD), dupilumab use was found to be linked with early (1 month) of patient-reported benefits that were maintained after 12 months of therapy.

• A total of 699 patients with AD who initiated dupilumab treatment were included in this prospective, longitudinal study in the clinical practice setting, to assess self-reported disease control and quality of life of these patients after initiating dupilumab.

• In the majority of the patients, adequate disease control (Atopic Dermatitis Control Tool total score) was achieved at month 1 with further improvement at month 12.

• Compared to baseline, a reduction in the use of other AD therapies was evident at each follow-up.

• With AD treatment, patient satisfaction was higher vs baseline at each follow-up to 85.1% at month 12.

• At each follow-up, reductions in flares, itch, skin symptoms, and improvements in sleep, health-related quality of life, and daily activities, relative to baseline, were experienced by patients.